我们和谁一起工作
18luck线策略
持续的压力, 加剧了COVID-19, are forcing oncology providers to transform existing cancer care models.
肿瘤学 is a unique and dynamic segment of the US healthcare system. 相关疾病的复杂性, 创新的步伐, and myriad treatment options can leave providers struggling to keep up. This clinical and technological innovation comes at a cost, approaching $100 billion annually; as a result, affordability has become a major concern for patients, 立法者, 和供应商都.
肿瘤学 providers are under pressure to find cost-control measures that ensure patients can afford the care they need while keeping cancer programs financially viable. The recent COVID-19 pandemic has intensified these issues, exposing flaws in the current operating model and accelerating innovation efforts. 肿瘤学 providers have significant challenges to overcome as they adapt business and operational practices in search of long-term sustainability.
Congress further delayed the Radiation 肿瘤学 (RO) Model, 预计将于1月1日开始, 2022. Participants can use this extra time to their advantage.
阅读更多
The new mandatory payment model is intended to align Medicare’s payments for Part B drugs with prices offered internationally for the same drugs, as well as remove incentives to unnecessarily 使用成本较高的药物.
阅读更多
As payers move to restrict hospital-based imaging, here are 6 recommendations to help hospitals mitigate near-term losses and diversify their imaging portfolios.
阅读更多
Explore the anticipated impact of the proposed CMS changes to the MPFS for CY 2021 to avoid possible financial losses for your organization.
阅读更多
